A Study of Osimertinib in Advanced NonSmall Cell Lung Cancer Patients with Exon20 Mutations in EGFR (EA5162)
A Study of Osimertinib in Advanced NonSmall Cell Lung Cancer Patients with Exon20 Mutations in EGFR (EA5162)
Trial Category:
Lung
Phase
II
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
This is a study of the drug Osimertinib in advanced non small cell lung cancer whose tumor is first tested for certain markers thought to respond to this drug.
